Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02224781
Title Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)



Ipilimumab + Nivolumab

Dabrafenib + Trametinib

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST